Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study
Name:
35790100.pdf
Size:
753.1Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Alderuccio, J. P.Ai, W. Z.
Radford, John A
Solh, M. M.
Ardeshna, K. M.
Lunning, M.
Hess, B.
Luigi Zinzani, P.
Stathis, A.
Carlo-Stella, C
Hamadani, M.
Kahl, B. S.
Ungar, D.
Kilavuz, T.
Yu, E.
Qin, Y. G.
Caimi, P. F.
Affiliation
University of Miami Miller School of Medicine, Miami, Florida, United StatesIssue Date
2022
Metadata
Show full item recordCitation
Alderuccio JP, Ai WZ, Radford J, Solh MM, Ardeshna KM, Lunning M, et al. Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood advances. 2022 Jul 5. PubMed PMID: 35790100. Epub 2022/07/06. eng.Journal
Blood AdvancesDOI
10.1182/bloodadvances.2022007782PubMed ID
35790100Additional Links
https://dx.doi.org/10.1182/bloodadvances.2022007782Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/bloodadvances.2022007782